

Effect of Mediterranean diet adapted to the Mexican population on indicators of metabolic risk in patients with obstructive sleep apnea. Randomized Controlled Trial.

Gittaim Pammela Torres San Miguel, María de la Luz Sevilla González, Eduardo López Ramírez, María Fernanda Flores López, Lubia Velázquez López

Submitted to: JMIR Research Protocols
on: February 11, 2025

Disclaimer: © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

Table of Contents

Original Manuscript..... 5

Supplementary Files..... 25

..... 25

0..... 25

Figures 26

Figure 1..... 27

Figure 2..... 28

Existing Peer-Review Reports from Funding Agencies (for protocols/proposals only)s 29

Existing Peer-Review Reports from Funding Agencies (for protocols/proposals only) 0..... 30

Effect of Mediterranean diet adapted to the Mexican population on indicators of metabolic risk in patients with obstructive sleep apnea. Randomized Controlled Trial.

Gittaim Pammela Torres San Miguel^{1,2}; María de la Luz Sevilla González³; Eduardo López Ramírez⁴; María Fernanda Flores López⁴; Lubia Velázquez López⁵

¹ Instituto Politécnico Nacional Mexico City MX

² Hospital General No 8 INSTITUTO MEXICANO DEL SEGURO SOCIAL Instituto Politécnico Nacional Mexico City MX

³ Escuela Superior de Medicina Instituto Politécnico Nacional Mexico City MX

⁴ Unidad de Investigación Biomédica Servicio de Geriátría del Sueño Mexican Social Security Institute Mexico City MX

⁵ Unidad de Investigación Biomédica Hospital Regional No 1. Dr Carlos MacGregor Sanchez Navarro- Mexican Social Security Institute Mexico City MX

Corresponding Author:

Lubia Velázquez López

Unidad de Investigación Biomédica

Hospital Regional No 1. Dr Carlos MacGregor Sanchez Navarro-

Mexican Social Security Institute

Gabriel Mancera 222. Colonia del Valle. Alcaldía Benito Juárez-

Mexico City

MX

Abstract

Background: Obstructive sleep apnea (OSA) is characterized by episodes of intermittent airway obstruction during deep sleep or REM. It is associated to cardiometabolic risk diseases. The base treatment is continuous positive airway pressure (CPAP), to which not all patients adapt. The Mediterranean diet has proven to be effective in reducing cardiovascular risk markers; however, it must be adapted to different populations. Among OSA patients, it can effectively reduce clinical entity and cardiometabolic risk, while improving quality of life and sleep.

Objective: To evaluate the effect of a Mediterranean diet adapted to Mexican diet versus a standard nutritional treatment on metabolic risk indicators in patients with obstructive sleep apnea.

Methods: A randomized, two-arm clinical trial will be conducted with OSA patients from the Hospital, Mexican Social Security Institute (Instituto Mexicano del Seguro Social, IMSS) in Mexico. Patients will be randomly included in the group assigned Mediterranean diet adapted to Mexican foods or in that given a standard diet for OSA. Fasting blood samples will be drawn after 6 and 12 months to identify glucose levels and lipid profiles. Anthropometric and body composition measurements will be taken, and adherence to diet will be recorded after 3, 6, and 12 months. Sleep quality, physical exercise, and life quality will be recorded basally and after 12 months.

Results: The protocol was authorized in 2024, and funding is sought for patient follow-up, including patients and RCT, in 2025. Recruiting will start in March 2025, and data analysis and results are expected to be completed by February 2026.

Conclusions: The results of the present RCT will contribute to evaluate the effect of a nutritional intervention adapted to OSA patients, seeking to reduce cardiovascular risk indicators in patients, improve their clinical condition, reduce OSA symptoms, and improve patients' quality of life. Clinical Trial: NCT06782737; <https://clinicaltrials.gov/study/NCT06278571>

(JMIR Preprints 11/02/2025:72513)

DOI: <https://doi.org/10.2196/preprints.72513>

Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

✓ Please make my preprint PDF available to anyone at any time (recommended).

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.
Only make the preprint title and abstract visible.

No, I do not wish to publish my submitted manuscript as a preprint.

2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible to all users.

Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in [JMIR Publications](#), my work will be made available to all users.

No. Please do not make my accepted manuscript PDF available to anyone.



Original Manuscript

Effect of Mediterranean diet adapted to the Mexican population on indicators of metabolic risk in patients with obstructive sleep apnea. Randomized Controlled Trial.

¹Coordinación de Jornada Acumulada, Hospital General No 8. Instituto Mexicano del Seguro Social. Ciudad de Ensenada, Baja California. México.

Gittaim Pammela Torres San Miguel¹ María de la Luz Sevilla González², Eduardo López Ramírez³, María Fernanda Flores López⁴ y Lubia Velázquez López⁵

1. Posgrado Escuela de Medicina. Instituto Politécnico Nacional/ Coordinación Clínica HGZ No 8, Ensenada Baja California. México.

2. Estudios de Posgrado e Investigación. Escuela de medicina. Instituto Politécnico Nacional. Ciudad de México, México.

³. Servicio de Geriátría y Clínica del sueño. Hospital Regional No. 1 “Dr. Carlos MacGregor Sánchez Navarro. Instituto Mexicano del Seguro Social. Ciudad de México, México.

⁴Unidad de Investigación en Epidemiología Clínica Hospital General Regional 1 “Dr. Carlos MacGregor Sánchez Navarro” Instituto Mexicano del Seguro Social. Ciudad de México, México.

Corresponding author:

Lubia Velázquez López

Email: lub.velazquez@gmail.com

Abstract

Background. Obstructive sleep apnea (OSA) is characterized by episodes of intermittent airway obstruction during deep sleep or REM. It is associated to cardiometabolic risk diseases. The base treatment is continuous positive airway pressure (CPAP), to which not all patients adapt. The Mediterranean diet has proven to be effective in reducing cardiovascular risk markers; however, it must be adapted to different populations. Among OSA patients, it can effectively reduce clinical entity and cardiometabolic risk, while improving quality of life and sleep. **Objective:** We aimed to evaluate the effect of a Mediterranean diet adapted to Mexican diet *versus* a standard nutritional treatment on metabolic risk indicators in patients with obstructive sleep apnea.

Methods. A randomized, two-arm clinical trial will be conducted with OSA patients from the Hospital, Mexican Social Security Institute (Instituto Mexicano del Seguro Social, IMSS) in Mexico. Patients will be randomly included in the group with Mediterranean diet adapted to Mexican foods. With a personalized diet plan adapted from the Mediterranean diet, prototype menus with Mexican foods adapted from the DM will be included for a higher consumption of fruits, vegetables, fiber-rich cereals and reduction of red meat. In addition to an illustrative plate to improve adherence. The standard diet group will receive standardized nutritional counseling for OSA patients. Fasting blood samples will be drawn after 6 and 12 months to identify glucose levels and lipid profiles. Anthropometric and body composition measurements will be taken, and adherence to diet will be recorded after 3, 6, and 12 months. Sleep quality, physical exercise, and life quality will be recorded basally and after 12 months. A multivariate logistic regression analysis will be performed, including the achievement of metabolic indicator control goals, sleep quality, and quality of life as outcome variables. This analysis will be adjusted for other variables that may be statistically significant in the bivariate analysis, such as sex, age and comorbidities, among others. Statistically significant differences between groups will be considered when the value of $p < 0.05$.

Results: The protocol was authorized in 2024, and funding is being sought for patient follow-up. All 120 patients (60 per group) will be included in 2025; recruitment will begin in March 2025. The clinical trial is expected to be completed in April 2026.

Conclusions: The results of the present study will contribute to evaluate the effect of a nutritional intervention adapted to OSA patients, seeking to reduce cardiovascular risk indicators in patients, improve their clinical condition, reduce OSA symptoms, and improve patients' quality of life.

Trial Registration: Clinical Trials.gov. NCT06782737; <https://clinicaltrials.gov/study/NCT06278571>

KEYWORDS: obstructive sleep apnea; obesity; hyperglycemia; hypercholesterolemia; mediterranean diet; nutritional therapy.

Introduction

Obstructive sleep apnea (OSA) is a disease characterized by the partial or total obstruction of airways during sleep [1]. The global prevalence of OSA has been reported to be between 9 and 38%, considering an apnea-hypopnea index (AHI) of ≥ 5 events/h; higher in men, advancing age, and urban dwelling [2]. In Mexico, an elevated risk of OSA of 27.3% in adults has been reported, and this risk increases as the body mass index is higher. [3]

OSA is estimated to be present in 60% of patients with metabolic syndrome, which can also include, diabetes, obesity, insulin resistance, systemic arterial hypertension, and dyslipidemia [4]. Overweight and obesity contribute to higher amounts of fat in dilator muscles of neck and tongue, thus increasing OSA. A positive correlation has been found between severe OSA and obesity in adult patients [5].

Daytime symptoms of OSA patients include, excessive daytime drowsiness, complaints of unrefreshing sleep, morning headaches resolved with breathing regulation, irritability, apathy, depression, difficulty to focus, and memory loss, among others [6]. The treatment of choice for OSA patients, CPAP, generates positive air pressure to reduce negative intrathoracic and upper airway pressure, limiting the repetitive hypoxia cycle in the patients; still, adherence is limited [7].

Weight loss in OSA patients is directly proportional to reduced respiratory events measured by AHI. This was reported in 89 men with OSA who reduced body weight by 7%, fat by 19%, and visceral adipose tissue by 26%, in addition to changes in lifestyle. As a result, OSA was reduced by 15% and 45% of the patients did not need CPAP anymore [8]. Evidence indicates the Mediterranean diet (MD) is widely cardioprotective and contributes to lowering cardiovascular risk and even death [9–11]. The PREDIMED study reported that an MD, mostly consisting of fruits, vegetables, white meat, and dried fruits or olive oil, reduced cardiovascular event symptoms in patients compared to those who followed a controlled diet. The MIMOSA study conducted with 187 adults with OSA showed that an intervention with MD or Mediterranean style had a better effect improving cardiometabolic indicators than a standard diet [12]. Additionally, the authors report a greater reduction in metabolic syndrome with MD in OSA patients, even when adjusting fluctuations in body weight as compared against a Mediterranean style or a standard diet [13, 14]. Fewer insomnia episodes have been linked to a greater adherence to MD in patients with OSA and insomnia [15]. Although it has shown to be

cardioprotective and improve metabolic indicators, MD must be adapted to other countries. In Mexico, there is scarce evidence on the modification of MD to the Mexican diet and its cardiometabolic effect in OSA patients. Therefore, the aim of this study is to evaluate the effect of a Mediterranean diet adapted to Mexican eating habits versus a standard nutritional treatment on metabolic risk indicators in patients with obstructive sleep apnea.

Methods

Study and population assignment

A randomized, two-arm clinical trial will be conducted with OSA patients from the Regional Hospital, Mexican Social Security Institute (Instituto Mexicano del Seguro Social, IMSS) in Mexico City with 12-month follow-up.

The sample size was calculated using the formula for difference in proportions, considering a confidence interval of 95% and a power of 80%. Weight loss is expected in 58% of the sample corresponding to the group given a MD adapted to Mexican population and in 30% of the group consuming a standard diet, as previously reported in the literature. A sample size of 49 patients per group was obtained and, considering losses of 20%, the total number of patients will be 120 [16].

Selection criteria

Inclusion criteria

Men and women aged 30–70 years, diagnosed with moderate and severe OSA will be included. Table 1 describes the inclusion and exclusion criteria.

Table 1. Selection criteria for patients with OSA included of the study	
Inclusion criteria:	
● Men and women ● Ages 30-70 years old ● Diagnosed with moderate or severe obstructive sleep apnea ● Use of Continuous positive airway pressure (CPAP)	
Exclusion criteria:	
● Anatomic alterations of the nose, oropharynx, or maxilla ● Chronic kidney disease under substantive renal function treatment. ● Decompensated heart failure ● Any type of cancer ● Neurological disease ● Diagnosis of depression	

- Refractory dyslipidemia
- Familial dyslipidemia
- Surgeries in the last 6 months
- Body mass index (BMI) >40 kg/m²

Study procedures

The study design is a randomized, two-arm clinical trial in patients with OSA. The patients will be referred by a specialist from the sleep clinic at the Hospital where the study will take place. Once the inclusion criteria are checked, the study, risks, and benefits will be explained to the patients, questions will be answered by the researchers, and the patients will sign informed consents to participate in the trial.

Software will be used for randomization, and patients will be assigned to either of the following groups:

- *Mediterranean Diet with Mexican Food*
- Standard diet

Sociodemographic and clinical variables

The medical researcher will conduct a clinical interview to obtain sociodemographic data, pathological background, present comorbidities, and current pharmacological treatment.

A medical questionnaire will be applied by the research team to collect sociodemographic data, pathological-clinical background, and non-pathological information. The patients will answer questions regarding age; clinical history, including pathological and non-pathological background; and pharmacological and non-pharmacological treatments.

Arterial blood pressure measurement

Arterial blood pressure will be measured by the medical team participating in the study, using a pre-gauged blood pressure cuff, and no smoking nor consumption of coffee or cola soft drinks in the previous 30 min. The patient will sit in a chair, with the back supported and feet straight on the floor. The left arm will be uncovered and supported on a flat table at heart level. The air chamber (balloon) must cover at least $\frac{3}{4}$ of the arm's length and at least 80% of its circumference.

Sleep variable measurement

During the first consultation at the Sleep Clinic, measurements of AHI and oxygen desaturation index will be recorded using CPAP, as part of the routine studies patients with OSA undergo. The study takes 7–8 h.

Polysomnography: PSG channels will be set up; they include electroencephalographic derivations and electrooculogram, electromyogram of chin and legs, respiratory flow signals from thermistor and/or nasal cannula, respiratory effort signals, continuous oxygen monitoring, electrocardiogram, and patient's body position. The study, lasting 4–6 h, will be carried out once and is part of a series of tests that OSA patients *undergo*.

Biochemical indicator measurement

Venous blood samples will be taken after fasting for 8–10 h to measure glucose, lipid profile (cholesterol, triglycerides, HDL cholesterol, and LDL cholesterol). Measurements will be recorded during the first consultations and after 6 and 12 months.

Anthropometric and body composition measurements

Body composition will be measured by bioimpedance, using an InBody 120 composition analyzer, to obtain fat percentage, fat mass, lean mass, and total body water. Body weight and height will be measured with the same analyzer. The patient must wear as little clothing as possible, without any metal objects (bracelets, earrings, rings, belt, and others). The patient will face forward, place their feet on the metal plates, and arms holding the metal bars and stretched out to the front in a 90 ° angle. Height will be measured using an InBody ultrasound stadiometer while the patient is in an upright anatomical position. Anthropometry will be recorded by two nutritionists previously standardized, using the method proposed by Habitch and according with the specifications by Lohman and colleagues [17, 18]. The body mass index (BMI) will be obtained from height and weight.

Waist circumference (WC) will be measured using a measuring tape halfway between the lowest rib and the top of the right hipbone. The average value of the second and third measurements will be used for analysis. Measurements will be taken during the first consultation and after 3, 6, and 12 months.

Sleep quality measurement

Sleep quality will be measured using Epworth sleepiness (ESS) scale which evaluates 8 items, each from 0 to 3 points, where 0 indicates the patient would never nod off, 1 indicates a small probability of nodding off or falling asleep, 2 indicates a moderate probability of nodding off or falling asleep, and 3 indicates a high probability of falling asleep. A score from 1 to 6 in the scale is considered regular sleep, one from 7 to 8 points is considered mild sleepiness, and one from 9 to 24 points at a pathological (abnormal) drowsiness [19].

Quality of life measurement

Quality of life will be measured using a Quebec Sleep Questionnaire (QSQ), which has been validated for the Hispanic population. It contains 32 items focused on measuring daily sleepiness (7, 16, 20, 27, 31, and 32), daytime symptoms (1, 10, 11, 14, 17, 18, 19, 23, 26, 29), nighttime symptoms (4, 9, 21, 22, 25, 28, 30), emotions (5, 6, 8, 15, 24), and social interactions (2, 3, 12, 13). The questionnaire will be applied basally and after 12-month follow-up [20].

Physical activity measurement

To measure the physical activity, the International Physical Activity Questionnaire (IPAQ) will be applied. The questionnaire contains 7 items that point at the physical activity carried out in the past seven days (hours, minutes, and days of the week). Physical activity will be classified after considering the metabolic equivalent of task (MET) values according to the activity (measurement unit of the test). Physical activity is classified in three categories: low, moderate, and high (25). It will be measured at the beginning of the trial, and after 6 and 12 months [21].

Nutritional intervention description

-Group with Mediterranean diet adjusted using Mexican food

The patients in the MD group will be given a normocaloric, personalized diet with the following distribution: 15–20% proteins, 50–55% carbohydrates, 25–30% fats, and <7% saturated fats, according to the recommendations for OSA patients. The Mifflin-St Jeor equation will be applied to calculate the caloric requirements. At the beginning of the intervention, 24-h reminders will be established to know dietary habits and adjust the diet to the patient's preferences, customs, and budget. A dietary plan will be designed using equivalent foods. The equivalents will be chosen from the Mexican system of equivalent foods, considering portions, amounts and preparation of each food. In it, typical foods of the Mexican diet can be found, along with their most common preparation and presentation; for instance: grilled, fried, baked, and uncooked (raw), among others [22].

The MD includes a variety of typical foods from European countries. Therefore, it is necessary to analyze their nutritional characteristics before adapting the diet to Mexican citizens particularly those OSA patients taking part in this study. After reviewing the literature, foods belonging to the Mexican diet were identified to show similar characteristics as those in the MD. As part of the adaptation, a comparative chart showing European and Mexican foods was created using the major food groups. Table 2 shows the most representative foods and their adaptation to the Mexican diet, which is explained simply to the patients.

Table 2. Mediterranean-Mexican Food: *Proposal for the adaptation of the Mediterranean Diet with Mexican food.*

Food Group/Equivalent	Mediterranean Diet	Foods in Mexico	Suggested portions and frequency of consumption
Fruits and vegetables	Fruits: Grapes, watermelon, strawberries, oranges Vegetables: Artichokes, asparagus, lettuce, bell peppers, spinach, broccoli.	Fruits: Guava, orange, mango, mamey, papaya, blackberry, banana Vegetables: Nopal, chayote, cucumber, mushrooms, purslane, quelites, chard, watercress, zucchini, bell pepper, green beans, jicama	Fruits: 1-2 servings per main meal Vegetables: >2 servings per main meal Total: At least 5 servings per day
Healthy Fats	Olive oil, olives, hazelnuts, almonds	Avocado, nuts, peanuts, corn oil, sunflower oil, pumpkin seeds, pistachios, sesame seeds	Olive oil: In every main meal Nuts, seeds, olives, avocado: 1-2 servings per day
Cereals	Whole wheat bread, pasta, rice, couscous	Whole wheat bread, pasta, rice, corn tortilla, oats, amaranth	Bread, pasta, rice, tortilla, oats: 1-2 servings per main meal
Tubers	Potatoes, sweet potatoes	Potatoes, sweet potatoes, yuca	Potatoes, sweet potatoes, yuca: <3 servings per week
Legumes	Lentils, chickpeas, beans, peas	Lentils, beans, chickpeas	Lentils, beans, chickpeas: >2 servings per week
Animal-based foods	Fish and seafood: Salmon, cod, squid, mussels, shrimp, oysters Low-fat dairy: Yogurt, cheese, milk White meat: Chicken, hen, turkey Eggs Red and processed meats: Beef, pork,	Fish and seafood: Tuna, sardines, trout, red snapper, tilapia Low-fat dairy: Yogurt, cheese, milk, cottage cheese, curd White meat: Chicken, hen, turkey Red and processed meats: Beef, pork, cold cuts	Fish: >2 servings per week Low-fat dairy: 2 servings per day White meat: 2 servings per week Eggs: 2-4 servings per week Red meat: <2 servings per week Processed meats:

	cold cuts		<1 serving per week
<i>This table provides examples of foods characteristic of the general Mexican population. It may vary according to the region of Mexico, seasonality, and accessibility for each patient.</i>			

In addition to the equivalency chart including the food groups of both diets, a healthy eating plate was also created as the strategy has been effective in Mexico, where the main foods for a healthy diet are presented in a plate [23]. From this strategy, a plate of MD in Mexico was designed, adapting foods that must be consumed according to the region, culture, preferences, and budget, considering easy access for OSA patients.

The multimedia Appendix 1. MD plate adapted with Mexican food.



To reinforce the meal plan given to this group, preestablished menus were designed containing foods typical in the MD, such as fruits, vegetables, whole grains, cereals, and white meat. The menus also promoted the intake of vegetable oils and common dried fruits in Mexico. The menus were designed to reach 1200, 1400, 1600, 1800, 2002, and 2200 calories. This group will also continue their common treatment with their physician or group of healthcare professionals as usual.

Adherence assessment of Mediterranean diet with Mexican food

Adherence to MD will be measured using the 14-point Mediterranean diet adherence screener

(MEDAS) questionnaire, consisting of 12 questions on the consumption frequency of foods and 2 questions on intake habits of foods considered part of the MD [24]. In this instrument, each question is scored 0 or 1. One point is given for using olive oil as main source of fat for cooking, preferring white meat over red meat, or for consuming: a) 4 or more spoons of olive oil/day; b) 2 or more vegetable portions/day; c) 3 or more pieces of fruit/day; d) less than 1 portion of red meat or sausage/day; e) less than 1 portion of animal fat/day; f) less than 1 sugary drink/day; g) 7 or fewer glasses of red wine/week; h) 3 or more portions of legumes/week; i) 3 or more portions of fish/week; j) fewer than 2 cakes or commercial baked goods/week; k) 3 or more portions of nuts/week; and l) a plate of traditional tomato, garlic and onion sauce twice or more/week. The total score ranges between 0 and 14 and allows to identify three levels of MD: low (0–6), medium (7–8), and high (≥ 9).


Standard diet (SD) group

Patients in the control group will be given a normocaloric diet with the following energy distribution: 15–20% proteins, 50–55% carbohydrates, 25–30% fats, and $< 7\%$ saturated fats, per the guidelines for adult OSA patients. The Mifflin-St Jeor equation will be applied to identify the caloric requirements of each patient. The energy needs and distribution will be administered as individual nutritional guidance regarding sleep hygiene measures and type of diet for weight loss according to age, sex, current body weight, and present comorbidities. At the beginning of the intervention, 24-h reminders will be set to know the daily diet. Patients will be given a pamphlet to reinforce healthy eating, and they will continue nutritional consultations with their physicians. This group will also continue the traditional treatment with their physician or group of healthcare professionals as usual.

Follow-up and study procedures

At the beginning of the trial and after 12 months, laboratory data (glucose and lipid profiles), clinical data, arterial blood pressure records, anthropometry, body composition, and dietary records of the previous 3 days will be obtained, along with the quality of life and sleep survey. All the patients will receive the written results and explanation in each clinical consultation, as shown in Multimedia Appendix 2.

Multimedia Appendix 2. Study follow-up and procedure.



Follow-up will continue after 3, 6, and 12 months for MD and 6 and 12 months for SD diet participants, who will attend consultation with nutritionist and medical team. In order to measure the adherence to the diet in both groups, the patients will register the 3 days prior to their clinical visit, two registrations from Monday to Friday and one on weekends. At each visit, nutritional guidelines will be given to improve adherence to the nutritional intervention. The study follow-up is shown in Table 3.

Table 3. Study Follow-Up and Procedure in Patients with OSA in Both Groups.

	Baseline	3 months	6 months	12 months
Collection of sociodemographic data	MD and SD			
Medical history	MD and SD			
Medical evaluation	MD and SD		MD and SD	MD and SD
Biochemical data	MD and SD			MD and SD
Arterial blood pressure and Anthropometric and body composition	MD and SD	MD	MD and SD	MD and SD

measurements				
Sleepiness with Epworth sleepiness scale	MD and SD	MD and SD	MD and SD	MD and SD
Quality of life with Quebec Sleep Questionnaire (QSQ)	MD and SD			MD and SD
Physical activity with IPAQ Questionary	MD and SD		MD and SD	MD and SD
Adherence to the diet intervention with records of the previous 3 days	MD and SD	MD	MD and SD	MD and SD
Adherence to the diet intervention with MEDAS Questionary	MD and SD	MD	MD and SD	MD and SD
Phone call follow-up		SD		

Group with Mediterranean Diet (MD). Group with Standard diet (SD).

Primary Outcomes

The primary objective of this clinical trial is to evaluate the effect of the MD adapted to the **Mexican diet versus a standard diet treatment** on metabolic risk indicators in OSA patients (body weight, fasting glucose, lipid profile, WC, and body composition).

The secondary outcomes are to evaluate the effect of the intervention on:

1. Sleep quality through ESS.
2. Changes in quality of life through QSQ.
3. Adherence to nutritional therapy intervention through records of meals corresponding to previous and MEDAS questionnaire.

Statistical analysis

The statistical analysis of the data will be carried out using SPSSv27. The study population will be described using the background, clinical, and pathological variables to characterize the sample of OSA participants. The Kolmogorov–Smirnov test will be used to identify the distribution of quantitative variables, for whose normal distribution measures of central tendency and dispersion will be estimated. For those with free distribution, mean and interquartile range will be used.

Measures of frequency and percentages will be used for sociodemographic and clinical qualitative variables, as well as those of patient proportion with and without glycemic control, and with and without cognitive impairment. A chi-square test will be used to compare the effect of mediterranean diet versus Standard diet on parameters of control and uncontrol of metabolic risk indicators. Depending on the data distribution, a Student's t test will be used to compare quantitative variables with parametric distribution between groups, and a Mann–Whitney U test will be conducted for free-distribution variables. A multivariate logistic regression analysis will be performed, including the achievement of metabolic indicator control goals, sleep quality, and quality of life as outcome variables. This analysis will be adjusted for other variables that may be statistically significant in the bivariate analysis, such as sex, age and comorbidities, among others. Statistically significant differences between groups will be considered when the value of $P < 0.05$.

Ethical Considerations

This clinical trial was submitted to the Ethics and Research Committee at HGR 1 “Dr Carlos MacGregor Sánchez Navarro”, IMSS under the registry number R-2024-3609-055. The protocol was registered at Clinical Trials.gov (NCT06782737). The aim of the study, risks, and benefits will be explained in detail to the participants who will freely chose to take part in the trial. They will provide a written consent describing each procedure in the trial and respect to information privacy. All the researchers participating receive annual training regarding better clinical practices related to research.

Results

The protocol was approved in 2024, and funding is being sought for patient follow-up, patient inclusion and execution of RCT in 2025. Recruiting will start in March 2025, while data analysis and expected results are to be completed by February 2026.

It is expected that there will be differences in the intervention groups of patients with OSA enrolled in the study: Measurement of blood pressure. Measurement of sleep variables. Measurement of biochemical indicators. Anthropometric and body composition measures. Measurement of sleep quality. Measurement of quality of life. We expect to find in patients with MD a higher proportion of cardiometabolic indicators in control, compared to patients in the group with S. We expect to find differences in multivariate analysis in control goals of cardiometabolic indicators, quality of sleep and quality of life of patients.

Discussion

This protocol aims to measure the impact of a MD adapted to the Mexican population on cardiovascular risk indicators, such as glucose, lipid profile, body weight and blood pressure in patients with OSA. In addition, as secondary objectives we seek to evaluate the effect of the MD on sleep quality and quality of life, as well as the improvement in diet quality.

There is enough evidence on the cardioprotective effect of MD, which is not only proven in European countries: There are clinical trials evaluating MD adapted to the Chilean population suffering metabolic syndrome [25]. It has been proven that interventions aimed at lifestyle improve AHI, showing a reduction by -4.55 events/h and improving weight and BMI among OSA patients; however, no effect on sleep and life quality has been found [26]. Despite the ample evidence supporting the cardioprotective benefits of the MD, its evaluation has been predominantly focused on patients with obesity, diabetes, and, to a lesser extent, patients with OSA. The impact of adapting the MD diet with food in Mexico has been examined to a lesser extent.

The relationship between cardiometabolic risk factors and sleep duration has been previously reported in 47 patients with OSA in a rural community in the southeastern United States. The authors reported that shorter sleep duration was associated with increased risk of hypertension, obesity, and impaired metabolic indicators. [27] The results of the present study suggest that an MD intervention with a preference for fruits, vegetables, high-fiber cereals, and white meat protein may improve cardiometabolic indicators.

Obesity and related diseases, like diabetes, hypertension, and dyslipidemia, represent a greater risk for OSA patients. Then, CPAP treatment combined with weight loss is an effective strategy to reduce cardiovascular risk [28]. Adaptation to the patient's tastes, customs, and budget is necessary to improve adherence to MD. This study seeks to adequate MD to the Mexican diet to make it accessible, since typical MD includes foods considered high-priced for the population receiving care at public healthcare institutions in Mexico.

Furthermore, improvement in cardiometabolic indicators, such a glucose, lipid profile, and weight loss, is likely. Patients are expected to lose 5–10% of their initial body weight, as reported by similar interventions [12].

Sleep quality in OSA patients could improve after the proposed nutritional intervention, while the number of obstructive respiratory events could be reduced given that the size of the oropharyngeal lumen is reduced because of body fat loss [29]. Besides the reduction in obesity, the diet is expected to improve fasting glucose, arterial blood pressure, and dyslipidemia in OSA patients taking part in

the trial. We also expect this trial to positively affect daytime drowsiness in the patients and improve their quality of life. This clinical trial would be one of the few conducted in Mexico with OSA patients where the implementation of low-cost strategies aims at improving cardiometabolic indicators and quality of life of those OSA patients that receive care at public healthcare institutions in Mexico.

Among the limitations of the present study, adherence to the DM could be found, therefore it is relevant to adapt the diet to the economic resources, habits and customs, which allows an adequate adherence to the DM. A personalized diet and a timely follow-up will be provided to reinforce adherence to the nutritional intervention. It has also been shown that the use of CPAP is limited in the population with OSA, since they do not consider it necessary for their condition or it is difficult to use it to sleep adequately [30]. One of the potential limitations of the study is the use of a self-reported tool to collect sleep quality information. There will be limitations to the generalizability of the effect of the intervention, as it will be a single-center study. In this sense, as one of the main variables is to measure the improvement in sleep quality, this could be improved with the use of CPAP, so its use will be recorded in the follow-up visits, to include it in the multivariate analysis.

Conclusion

This study seeks to contribute with improving the diet of patients with OSA, thus enhancing the cardiometabolic risk indicators and reducing the patients' risk of cardiovascular diseases. In addition, we expect to improve the patients' sleep quality and lifestyle. We consider this intervention will be useful to create a proposal including a Mediterranean diet adapted to Mexican habits that improves the dietary needs of OSA patients and similarly those of patients with diabetes, obesity, hypertension, and other comorbidities.

Acknowledgments

The authors would like to thank the authorities at Hospital Regional No 1 "Dr Carlos MacGregor Sánchez Navarro" for providing the conditions to carry out this study.

Data availability

The data obtained from the clinical trial will not be available publicly to protect the privacy of the patients' information. Still, they will be available through the author via correspondence and once there is a justification for the data analysis.

Authors' contributions

GT and LV were responsible for the conceptualization, research, study methodology, and final drafting of the manuscript. MS, EL and FF performed the methodology, reviewed and edited the manuscript.

Conflicts of interest

None declared

Abbreviations

- CPAP: Continuous positive airway pressure
- OSA: Obstructive sleep apnea
- IMSS: Instituto Mexicano del Seguro Social
- AHI: apnea-hypopnea index
- PSG: Polysomnography
- BMI: Body Mass Index
- WC: Waist circumference
- MD: Mediterranean diet
- SD: Standard diet
- ESS: Epworth Sleepiness Scale
- QSQ: Quebec Sleep Questionnaire
- IPAQ: International Physical Activity Questionnaire
- MET: Metabolic Equivalent Task
- MEDAS: Mediterranean Diet Adherence Screener

References

1. Park JG, Ramar K, Olson EJ. Updates on definition, consequences, and management of obstructive sleep apnea. In: Mayo Clinic Proceedings. Elsevier; 2011.
2. Senaratna CV, Perret JL, Lodge CJ, Lowe AJ, Campbell BE, Matheson MC, et al. Prevalence of obstructive sleep apnea in the general population: a systematic review. Sleep medicine reviews. 2017;34:70-81.
3. Guerrero-Zúñiga S, Gaona-Pineda EB, Cuevas-Nasu L, Torre-Bouscoulet L, Reyes-Zúñiga

- M, Shamah-Levy T, et al. Prevalencia de síntomas de sueño y riesgo de apnea obstructiva del sueño en México. *Salud publica de Mexico*. 2018;60(3):347-55.
4. Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. *Journal of the American College of Cardiology*. 2013;62(7):569-76.
 5. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. *American journal of epidemiology*. 2013;177(9):1006-14.
 6. Gottlieb DJ, Punjabi NM. Diagnosis and management of obstructive sleep apnea: a review. *Jama*. 2020;323(14):1389-400.
 7. Lorenzi-Filho G, Almeida FR, Strollo PJ. Treating OSA: Current and emerging therapies beyond CPAP. *Respirology*. 2017;22(8):1500-7.
 8. Carneiro-Barrera A, Amaro-Gahete FJ, Guillén-Riquelme A, Jurado-Fasoli L, Sáez-Roca G, Martín-Carrasco C, et al. Effect of an interdisciplinary weight loss and lifestyle intervention on obstructive sleep apnea severity: the INTERAPNEA randomized clinical trial. *JAMA Network Open*. 2022;5(4):e228212-e.
 9. Laffond A, Rivera-Picón C, Rodríguez-Muñoz PM, Juárez-Vela R, Ruiz de Viñaspre-Hernández R, Navas-Echazarreta N, et al. Mediterranean Diet for Primary and Secondary Prevention of Cardiovascular Disease and Mortality: An Updated Systematic Review. *Nutrients*. 2023;15(15).
 10. Rosato V, Temple NJ, La Vecchia C, Castellan G, Tavani A, Guercio V. Mediterranean diet and cardiovascular disease: a systematic review and meta-analysis of observational studies. *Eur J Nutr*. 2019;58(1):173-91.
 11. Martínez-González MA, Gea A, Ruiz-Canela M. The Mediterranean Diet and Cardiovascular Health. *Circ Res*. 2019;124(5):779-98.
 12. Georgoulis M, Yiannakouris N, Kechribari I, Lamprou K, Perraki E, Vagiakis E, et al. Cardiometabolic Benefits of a Weight-Loss Mediterranean Diet/Lifestyle Intervention in Patients with Obstructive Sleep Apnea: The "MIMOSA" Randomized Clinical Trial. *Nutrients*. 2020;12(6).
 13. Georgoulis M, Yiannakouris N, Kechribari I, Lamprou K, Perraki E, Vagiakis E, et al. Sustained improvements in the cardiometabolic profile of patients with obstructive sleep apnea after a weight-loss Mediterranean diet/lifestyle intervention: 12-month follow-up (6 months post-intervention) of the "MIMOSA" randomized clinical trial. *Nutr Metab Cardiovasc Dis*. 2023;33(5):1019-28.
 14. Martínez-González MA, Salas-Salvadó J, Estruch R, Corella D, Fitó M, Ros E. Benefits of the Mediterranean Diet: Insights From the PREDIMED Study. *Prog Cardiovasc Dis*. 2015;58(1):50-

60.

15. Kechribari I, Kontogianni MD, Georgoulis M, Lamprou K, Critselis E, Vagiakis E, et al. Association of adherence to the Mediterranean diet and physical activity habits with the presence of insomnia in patients with obstructive sleep apnea. *Sleep Breath*. 2022;26(1):89-97.

16. Ros E, Martínez-González MA, Estruch R, Salas-Salvadó J, Fitó M, Martínez JA, et al. Mediterranean diet and cardiovascular health: Teachings of the PREDIMED study. *Adv Nutr*. 2014;5(3):330s-6s.

17. Lohman TG, Roche AF, Martorell R. Anthropometric standardization reference manual. Champaign, IL: Human Kinetics; 1988.

18. Habicht J-P. Estandarización de métodos epidemiológicos cuantitativos sobre el terreno. *Boletín de la Oficina Sanitaria Panamericana (OSP)*; 76 (5), mayo 1974. 1974.

19. Johns MW. A new perspective on sleepiness. *Sleep and biological rhythms*. 2010;8:170-9.

20. Catalán P, Martínez A, Herrejón A, Chiner E, Martínez-García MÁ, Sancho-Chust JN, et al. Consistencia interna y validez de la versión española del cuestionario de calidad de vida específico para el síndrome de apneas-hipopneas del sueño Quebec Sleep Questionnaire. *Archivos de Bronconeumología*. 2012;48(4):107-13.

21. Medina C, Barquera S, Janssen I. Validity and reliability of the International Physical Activity Questionnaire among adults in Mexico. *Revista Panamericana de Salud Pública*. 2013;34:21-8.

22. Lizaaur ABP, González BP, Becerra ALC, Galicia IF. Sistema mexicano de alimentos equivalentes: Fomento de Nutrición y Salud; 2014.

23. Gobierno de México. Guías Alimentarias para la Población Mexicana. 2023. Disponible en: [<https://www.gob.mx/promosalud/documentos/guias-alimentarias-para-la-poblacion-mexicana?state=published>].

24. Schröder H, Fitó M, Estruch R, Martínez-González MA, Corella D, Salas-Salvadó J, et al. A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. *The Journal of nutrition*. 2011;141(6):1140-5.

25. Echeverría G, Samith B, von Schultzendorf A, Pinto V, Martínez X, Sara D, et al. Mediterranean diet and psychological well-being intervention to reverse metabolic syndrome in Chile (CHILEMED trial). *Contemp Clin Trials Commun*. 2023;35:101167.

26. Thomasouli MA, Brady EM, Davies MJ, Hall AP, Khunti K, Morris DH, et al. The impact of diet and lifestyle management strategies for obstructive sleep apnoea in adults: a systematic review and meta-analysis of randomised controlled trials. *Sleep Breath*. 2013;17(3):925-35.

27. Knowlden AP, Winchester LJ, MacDonald HV, Geyer JD, Higginbotham JC. Associations

Among Cardiometabolic Risk Factors, Sleep Duration, and Obstructive Sleep Apnea in a Southeastern US Rural Community: Cross-Sectional Analysis From the SLUMBRx-PONS Study. JMIR Form Res. 2024;8:e54792.

28. Salman LA, Shulman R, Cohen JB. Obstructive Sleep Apnea, Hypertension, and Cardiovascular Risk: Epidemiology, Pathophysiology, and Management. Curr Cardiol Rep. 2020;22(2):6.

29. Papandreou C, Schiza SE, Bouloukaki I, Hatzis CM, Kafatos AG, Siafakas NM, et al. Effect of Mediterranean diet versus prudent diet combined with physical activity on OSAS: a randomised trial. Eur Respir J. 2012;39(6):1398-404.

30. Laursen DH, Rom G, Banghøj AM, Tarnow L, Schou L. Improving Diabetes Self-management by Providing Continuous Positive Airway Pressure Treatment to Patients With Obstructive Sleep Apnea and Type 2 Diabetes: Qualitative Exploratory Interview Study. JMIR Form Res. 2021;5(7):e2706

Supplementary Files

Untitled.

URL: <http://asset.jmir.pub/assets/043ab69671b14dd1a8581c16f2370311.pdf>

Once the modifications requested by the review of the research and ethics committee were made, this protocol was approved.


URL: <http://asset.jmir.pub/assets/6d72bbd483d5334f0ffd6d971d41f0ca.pdf>

Figures

MD plate adapted with Mexican food.



Study follow-up and procedure.



Existing Peer-Review Reports from Funding Agencies (for protocols/proposals only)s

Peer review of the research protocol.

URL: <http://asset.jmir.pub/assets/6bd5d6b4655fc410b5da6e4320517760.pdf>

